Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Here, we study the intricate relationship between gut microbiota and host cometabolic phenotypes associated with dietary-induced impaired glucose homeostasis and nonalcoholic fatty liver disease (NAFLD) in a mouse strain (129S6) known to be susceptible to these disease traits, using plasma and urine metabotyping, achieved by (1)H NMR spectroscopy. Multivariate statistical modeling of the spectra shows that the genetic predisposition of the 129S6 mouse to impaired glucose homeostasis and NAFLD is associated with disruptions of choline metabolism, i.e., low circulating levels of plasma phosphatidylcholine and high urinary excretion of methylamines (dimethylamine, trimethylamine, and trimethylamine-N-oxide), coprocessed by symbiotic gut microbiota and mammalian enzyme systems. Conversion of choline into methylamines by microbiota in strain 129S6 on a high-fat diet reduces the bioavailability of choline and mimics the effect of choline-deficient diets, causing NAFLD. These data also indicate that gut microbiota may play an active role in the development of insulin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A causal role for the involvement of gut microbes is in part based on the fulfillment of one of Koch’s postulates - namely, the transmission of a disease related phenotype with transplantation of gut microbial organisms to a new host (Cho and Blaser, 2012; Cox et al., 2014; Dumas et al., 2006; Gregory et al., 2015; Koch, 1880; Sandhu and Chase, 1986).”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Dumas et al., 2006
In the citing paper
“Interestingly, dysbiotic microbiota from mice fed a high-fat diet metabolize and convert dietary choline into methylamines, resulting in low circulating levels of plasma phosphatidylcholine60.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [60]
In the citing paper
“Serum and urinary concentrations of methylamines including TMAO were associated with the development of nonalcoholic fatty liver and impairment of glucose metabolism in high-fat-fed 129S6 mice (39).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [39]
In the citing paper
“It has been demonstrated that the gut microbiota can play a role in the development of metabolic abnormalities such as insulin resistance and nonalcoholic fatty liver disease76,77.”
From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [77]
Citations
Cites
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Host-Bacterial Mutualism in the Human Intestine
Bäckhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A., & Gordon, J. I. (2005) · Science · doi:10.1126/science.1104816 · Cited by 5,277
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999) · Xenobiotica · doi:10.1080/004982599238047 · Cited by 3,895
Self-citationMetabonomics: a platform for studying drug toxicity and gene function
Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd728 · Cited by 1,914
Self-citation
Research works printed but not linked: 2
- A. L. Buchman, M. D. Dubin, A. A. Moukarzel, D. J. Jenden, M. Roch, K. M. Rice, J. Gornbein, M. E. Ament Hepatology 22, 1399–1403 (1995).
- S. H. Zeisel, J. S. Wishnok, J. K. Blusztajn J. Pharmacol. Exp. Ther. 225, 320–324 (1983).
Cited by
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760
Self-citationFunctional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Turnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.015 · Cited by 2,915
“Each transporter involves three linked enzymes that act as phosphoryl group recipients and donors: two are cytoplasmic enzymes that act on all imported PTS carbohydrates (HPr and EI), and the other is a carbohydrate-specific complex (EII) comprising one or two hydrophobic integral membrane domains (EIIC/D) and two hyd…”
BackgroundInfluentialMetabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677
“Normal host activities, including the processing of nutrients and the regulation of the immune system, are affected by the intestinal microbiome (2, 3), and the microbiome has been implicated in the pathogenesis of diseases such as nonalcoholic steatohepatitis (4), allergy (5), the formation of gallstones (6), and inf…”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
“insulin resistance, which suggests that the microbiota and/or microbiota-regulated host factors might influence energy absorption, adiposity, systemic inflammation, and development of insulin resistance.(35,36) Endotoxin and Its Role in Obesity.”
BackgroundPlovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Self-citationThe gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
Dysbiosis of the gut microbiota in disease
Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.26191 · Cited by 1,710
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Impact of the gut microbiota on inflammation, obesity, and metabolic disease
Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., & Dumas, M.-E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0303-2 · Cited by 1,438
Self-citationIncreased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
“9) 0 Villi ZO-1 nuclei (%) 7 (4-12) 1 (0-3) 0.”
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
“…based on the fulfillment of one of Koch's postulates: namely, the transmission of a disease-related phenotype with the transplantation of gut microbial organisms to a new host (Cho and Blaser, 2012; Cox et al., 2014; Dumas et al., 2006; Gregory et al., 2015; Koch, 1880; Sandhu and Chase, 1986).”
BackgroundMinireview: Gut microbiota: The neglected endocrine organ
Clarke, G., Stilling, R. M., Kennedy, P. J., Stanton, C., Cryan, J. F., & Dinan, T. G. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1108 · Cited by 1,192
Symbiotic gut microbes modulate human metabolic phenotypes
Li, M., Wang, B., Zhang, M., Rantalainen, M., Wang, S., Zhou, H., Zhang, Y., Shen, J., Pang, X., Zhang, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712038105 · Cited by 1,144
“prausnitzii is particularly intriguing because dimethylamine is a product of microbial catabolism of dietary choline (by trimethylamine) that has previously been linked to high-fat diet-induced insulin resistance, fatty liver, and type 2 diabetes in experimental mice (10), and in other studies a low Bacteroidetes-to-F…”
BackgroundSelf-citationThe gut microbiota at the intersection of diet and human health
Gentile, C. L., & Weir, T. L. (2018) · Science · doi:10.1126/science.aau5812 · Cited by 1,049
Bennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070
“Numerous reports in the literature have shown that there is genetic control of the composition of gut flora (Benson et al., 2010; Dumas et al., 2006; Kovacs et al., 2011; Turnbaugh et al., 2010).”
BackgroundNew hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre?
Fardet, A. (2010) · Nutrition Research Reviews · doi:10.1017/s0954422410000041 · Cited by 1,030
“Results are convincing in that new metabolic effects have been unravelled using this new open approach, for example, the role of symbiotic microbiota in triggering diet-induced mechanisms of steatosis((337)) or some specific metabolic pathway disturbances in diabetic rats((338)), thus improving our understanding of di…”
BackgroundThe role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Interactions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
The Human Gut Microbiome – A Potential Controller of Wellness and Disease
Kho, Z. Y., & Lal, S. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01835 · Cited by 1,104
Human Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., Chen, Y., & Ji, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071108 · Cited by 946
“Accumulating evidence indicates that the gut microbiota is involved in host metabolism by increased energy extraction, immune system modulation, and altered lipid metabolism, all which have been demonstrated to contribute to progression to T2DM [13,50–52].”
BackgroundCommensal bacteria at the interface of host metabolism and the immune system
Brestoff, J. R., & Artis, D. (2013) · Nature Immunology · doi:10.1038/ni.2640 · Cited by 945
Murphy, E. F., Cotter, P. D., Healy, S., Marques, T. M., O'Sullivan, O., Fouhy, F., Clarke, S. F., O'Toole, P. W., Quigley, E. M., Stanton, C., et al. (2010) · Gut · doi:10.1136/gut.2010.215665 · Cited by 946
The journal of clinical investigation
(1994) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(94)92394-9 · Cited by 1,198
Dewulf, E. M., Cani, P. D., Claus, S. P., Fuentes, S., Puylaert, P. G., Neyrinck, A. M., Bindels, L. B., de Vos, W. M., Gibson, G. R., Thissen, J.-P., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303304 · Cited by 825
“Dumas et al have demonstrated that mice developing insulin resistance and non-alcoholic fatty liver disease have lower levels of PC, leading to an impairment of very low density lipoprotein secretion and, thereby, hepatic triglycerides accumulation.(54) Nevertheless, other studies have shown that PC levels are higher…”
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments
Swann, J. R., Want, E. J., Geier, F. M., Spagou, K., Wilson, I. D., Sidaway, J. E., Nicholson, J. K., & Holmes, E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006734107 · Cited by 726
Self-citationMolecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Hoyles, L., Fernández-Real, J.-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., Heymes, C., Luque, J. L., Anthony, E., Barton, R. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0061-3 · Cited by 720
Self-citationMicrobial conversion of choline to trimethylamine requires a glycyl radical enzyme
Craciun, S., & Balskus, E. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215689109 · Cited by 701
“This microbe–host metabolic interaction has been linked to multiple diseases, including the inherited metabolic disorder trimethylaminuria (fish-malodor syndrome) (16), nonalcoholic fatty liver disease (17), and most recently atherosclerosis and cardiovascular disease (18).”
BackgroundIntestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Metabolomics-based methods for early disease diagnostics
Gowda, G. N., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., & Raftery, D. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.5.617 · Cited by 692
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
“While we can synthesize much of our requirements, we still need to consume some choline in our diet or else develop a deficiency state, which is characterized by fatty liver, altered one-carbon methyl donor metabolic pathways, and neurologic disorder (19, 32, 35, 36).”
BackgroundJaneiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M. (2018) · Nutrients · doi:10.3390/nu10101398 · Cited by 631
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T., & Nagy, L. E. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120026 · Cited by 628
“For example, in models of high-fatdiet-induced NAFLD/NASH, hepatocytes exhibit activation of inflammasomes (26), as well as activation via HMGB-1, an important endogenous danger signal (69).”
InfluentialFrom NAFLD to NASH to cirrhosis—new insights into disease mechanisms
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.149 · Cited by 609
Collins, S. M., & Bercik, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.075 · Cited by 612
Interactions Between Gut Microbiota and Host Metabolism Predisposing to Obesity and Diabetes
Musso, G., Gambino, R., & Cassader, M. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-012510-175505 · Cited by 598
“(55) tested the effects of switching from a low-fat diet to a 40% high-fat diet on plasma and urine metabolic 1H NMR profiles in the 129S6 mouse (a model of insulin resistance, NAFLD, impaired glucose tolerance, dyslipidemia, and obesity) and in the BALBc mouse, which is resistant to these phenotypes.”
BackgroundSpencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.049 · Cited by 593
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“Choline deficiency has been linked to liver disease for a long time (300), but recently high-fat diets have been linked to a microbiota that converts dietary choline into methylamines producing a choline deficiency and NASH (301).”
BackgroundScalbert, A., Brennan, L., Fiehn, O., Hankemeier, T., Kristal, B. S., van Ommen, B., Pujos-Guillot, E., Verheij, E., Wishart, D., & Wopereis, S. (2009) · Metabolomics · doi:10.1007/s11306-009-0168-0 · Cited by 565
“7) to guide the development of analytical metabolomics platforms.”
BackgroundGut microbiota dysbiosis in patients with non-alcoholic fatty liver disease
Shen, F., Zheng, R.-D., Sun, X.-Q., Ding, W.-J., Wang, X.-Y., & Fan, J.-G. (2017) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/s1499-3872(17)60019-5 · Cited by 563
Regulation of inflammation by microbiota interactions with the host
Blander, J. M., Longman, R. S., Iliev, I. D., Sonnenberg, G. F., & Artis, D. (2017) · Nature Immunology · doi:10.1038/ni.3780 · Cited by 646
Wang, Z., Tang, W. H. W., Buffa, J. A., Fu, X., Britt, E. B., Koeth, R. A., Levison, B. S., Fan, Y., Wu, Y., & Hazen, S. L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu002 · Cited by 559
Understanding the role of gut microbiome–host metabolic signal disruption in health and disease
Holmes, E., Li, J. V., Athanasiou, T., Ashrafian, H., & Nicholson, J. K. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.05.006 · Cited by 541
Self-citationGut microbiota and metabolic syndrome
Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., & Colecchia, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16079 · Cited by 534
Thematic Review Series: Glycerolipids. Phosphatidylcholine and choline homeostasis
Li, Z., & Vance, D. E. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r700019-jlr200 · Cited by 636
“deficiency and nonalcoholic fatty liver disease (90).”
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
“Indeed, it was shown that NAFLD is associated with lower levels of phosphatidylcholine and higher levels of TMA in the blood, implicating the role of microbiota in the imbalance of choline metabolic flux (Dumas et al , 2006).”
Huang, W., Metlakunta, A., Dedousis, N., Zhang, P., Sipula, I., Dube, J. J., Scott, D. K., & O'Doherty, R. M. (2010) · Diabetes · doi:10.2337/db09-0016 · Cited by 520
“Furthermore, it is now well-established that obesity alters the composition of the gut bacterial population (43-46), that there is”
BackgroundThe microbiota–gut–brain axis in obesity
Torres-Fuentes, C., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30147-4 · Cited by 612
Francque, S. M., van der Graaff, D., & Kwanten, W. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.005 · Cited by 556
“The intestinal microbiome activitymay contribute to both steatosis, due to prompt a relative choline-deficiency, and to increased levels of produced TMA out of this choline [147].”
BackgroundA top‐down systems biology view of microbiome‐mammalian metabolic interactions in a mouse model
Martin, F. J., Dumas, M., Wang, Y., Legido‐Quigley, C., Yap, I. K. S., Tang, H., Zirah, S., Murphy, G. M., Cloarec, O., Lindon, J. C., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100153 · Cited by 474
“These observations are consistent with previous findings that the microbiota promote storage of triglycerides in adipocytes via indirect modulation of cellular fatty acids uptake, secretion of apolipoproteins and adipocyte triglyceride accumulation (Backhed et al, 2004; Dumas et al, 2006).”
BackgroundResultInfluentialSelf-citationGut microbiota: a potential new territory for drug targeting
Jia, W., Li, H., Zhao, L., & Nicholson, J. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2505 · Cited by 475
“Emerging 'omics' technologies, such as metagenomics and metabonomics , are now being applied to the study of the gut microbial ecology at the molecular level, generating new insights and opportunities to reveal the medical functions of the gut microbiota to human healt”
BackgroundSelf-citationZhang, L. S., & Davies, S. S. (2016) · Genome Medicine · doi:10.1186/s13073-016-0296-x · Cited by 500
“potentially important microbial metabolites that derive from the gut microbes [4–10], that are enriched or depleted in diseased individuals [11–30], or that can be used to predict physiological response to foods or other interventions [31, 32] (Table 1).”
BackgroundTrimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease
Zeisel, S. H., & Warrier, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064732 · Cited by 475
“Serum and urinary concentrations of methylamines including TMAO were associated with the development of nonalcoholic fatty liver and impairment of glucose metabolism in high-fat-fed 129S6 mice (39).”
BackgroundKirpich, I. A., Solovieva, N. V., Leikhter, S. N., Shidakova, N. A., Lebedeva, O. V., Sidorov, P. I., Bazhukova, T. A., Soloviev, A. G., Barve, S. S., McClain, C. J., et al. (2008) · Alcohol · doi:10.1016/j.alcohol.2008.08.006 · Cited by 488
“Lastly, 129S6 mice that are sensitive to both alcoholic and nonalcoholic fatty liver disease have a unique gut microbiota, which disrupts intestinal choline metabolism to produce a marginally choline deficient mouse (Dumas et al., 2006).”
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
“Germ-free mice do not excrete trimethylamine, supporting an essential role for the gut microbiota in the conversion of choline to this compound”
BackgroundCholine metabolism provides novel insights into nonalcoholic fatty liver disease and its progression
Corbin, K. D., & Zeisel, S. H. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834e7b4b · Cited by 502
Orešič, M., Simell, S., Sysi-Aho, M., Näntö-Salonen, K., Seppänen-Laakso, T., Parikka, V., Katajamaa, M., Hekkala, A., Mattila, I., Keskinen, P., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081800 · Cited by 449
Biomarkers in nutritional epidemiology: applications, needs and new horizons
Jenab, M., Slimani, N., Bictash, M., Ferrari, P., & Bingham, S. A. (2009) · Human Genetics · doi:10.1007/s00439-009-0662-5 · Cited by 448
“In animal models, metabolic proWling approaches have shown that gut microbiota play an active role in insulin resistance (Dumas et al. 2006), which can be modulated by diet (Minich and Bland 2008).”
BackgroundObesity, Diabetes, and Gut Microbiota
Musso, G., Gambino, R., & Cassader, M. (2010) · Diabetes Care · doi:10.2337/dc10-0556 · Cited by 665
“2) gut microbiota on a high-fat diet may convert dietary choline into hepatotoxic methylamines, reducing choline bioavailability of choline, which is necessary for the assembly and secretion of VLDLs and eventually promoting hepatic steatosis, IR, and lipoperoxidation (6).”
BackgroundThe links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Fava, F., Gitau, R., Griffin, B. A., Gibson, G. R., Tuohy, K. M., & Lovegrove, J. A. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.33 · Cited by 434
The Gut Microbial Endocrine Organ: Bacterially Derived Signals Driving Cardiometabolic Diseases
Brown, J. M., & Hazen, S. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-060513-093205 · Cited by 438
“Within the last decade, there have been numerous reports linking metaorganismal pathways to human diseases including obesity (9,11), diabetes (12,13), nonalcoholic fatty liver disease (14), osteoporosis (15), cancer (16–18), and innate/adaptive immune responses (19,20).”
BackgroundKetone body metabolism and cardiovascular disease
Cotter, D. G., Schugar, R. C., & Crawford, P. A. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2012 · Cited by 440
Martin, F. J., Wang, Y., Sprenger, N., Yap, I. K. S., Lundstedt, T., Lek, P., Rezzi, S., Ramadan, Z., van Bladeren, P., Fay, L. B., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb4100190 · Cited by 421
“…strategies have been successfully applied to characterizing the metabolic consequences of nutritional intervention (Rezzi et al, 2007; Wang et al, 2007) the effects of the gut microflora on mammalian metabolism (Martin et al, 2006, 2007a, b) and mechanisms of insulin-resistance (Dumas et al, 2006).”
BackgroundInfluentialSelf-citationSalzman, N. H., Underwood, M. A., & Bevins, C. L. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.04.002 · Cited by 414
Bacterial Community Mapping of the Mouse Gastrointestinal Tract
Gu, S., Chen, D., Zhang, J.-N., Lv, X., Wang, K., Duan, L.-P., Nie, Y., & Wu, X.-L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074957 · Cited by 443
“microbial composition has been hypothesized to be involved in a range of diseases outside the gut, such as diabetes [3], obesity [4], fatty liver[5], inflammatory bowel diseases [6], anxiety [7] and even cancer [8].”
BackgroundRole of the gut microbiota in defining human health
Fujimura, K. E., Slusher, N. A., Cabana, M. D., & Lynch, S. V. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.14 · Cited by 407
Microbes and the gut‐brain axis
Bercik, P., Collins, S. M., & Verdu, E. F. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01906.x · Cited by 417
Global systems biology, personalized medicine and molecular epidemiology
Nicholson, J. K. (2006) · Molecular Systems Biology · doi:10.1038/msb4100095 · Cited by 388
Self-citationMouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding
Montgomery, M. K., Hallahan, N. L., Brown, S. H., Liu, M., Mitchell, T. W., Cooney, G. J., & Turner, N. (2013) · Diabetologia · doi:10.1007/s00125-013-2846-8 · Cited by 415
“Similarly, BALB/c mice have been previously reported as being either prone [47] or resistant [48] to dietinduced hepatic lipid accumulation.”
BackgroundDeficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease
Hernández-Alvarez, M. I., Sebastián, D., Vives, S., Ivanova, S., Bartoccioni, P., Kakimoto, P., Plana, N., Veiga, S. R., Hernández, V., Vasconcelos, N., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.010 · Cited by 400
“0 J) IP Mfn2 Mfn2 (1-613) (expressed in liver and purified)”
BackgroundInfluentialZhang, C., Yin, A., Li, H., Wang, R., Wu, G., Shen, J., Zhang, M., Wang, L., Hou, Y., Ouyang, H., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.07.007 · Cited by 416
“This suggests that proportionally more of the fatderived choline in the interventional diet was absorbed andmetabolized by the humanhost instead of undergoing fermentation to TMA by bacteria in the gut (Dumas et al., 2006).”
BackgroundSelf-citationChu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354
Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet
Gao, X., Liu, X., Xu, J., Xue, C., Xue, Y., & Wang, Y. (2014) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2014.03.001 · Cited by 360
A metabolomics pipeline for the mechanistic interrogation of the gut microbiome
Han, S., Van Treuren, W., Fischer, C. R., Merrill, B. D., DeFelice, B. C., Sanchez, J. M., Higginbottom, S. K., Guthrie, L., Fall, L. A., Dodd, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03707-9 · Cited by 409
Colonic bacterial metabolites and human health
Russell, W. R., Hoyles, L., Flint, H. J., & Dumas, M.-E. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.07.002 · Cited by 350
Self-citationMediterranean diet and nonalcoholic fatty liver disease
Anania, C., Perla, F. M., Olivero, F., Pacifico, L., & Chiesa, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2083 · Cited by 353
Chen, Y.-M., Liu, Y., Zhou, R.-F., Chen, X.-L., Wang, C., Tan, X.-Y., Wang, L.-J., Zheng, R.-D., Zhang, H.-W., Ling, W.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep19076 · Cited by 358
Trace Amines and Their Receptors
Gainetdinov, R. R., Hoener, M. C., & Berry, M. D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015305 · Cited by 384
“…and insulin, with insulin decreasing FMO3 levels in a sexually dimorphic manner (Miao et al., 2015), and dysregulated trimethylamine metabolism has been implicated in the pathology of both obesity and diabetes (Dumas et al., 2006; Toye et al., 2007), including in humans (Elliott et al., 2015).”
BackgroundAn Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 372
Gut microbiota, a new frontier to understand traditional Chinese medicines
Feng, W., Ao, H., Peng, C., & Yan, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.024 · Cited by 377
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes
Claus, S. P., Tsang, T. M., Wang, Y., Cloarec, O., Skordi, E., Martin, F., Rezzi, S., Ross, A., Kochhar, S., Holmes, E., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.56 · Cited by 334
“Metabonomic approaches combining spectroscopic profil- ing techniques with pattern recognition analysis have proved useful in the assessment of the systemic metabolic responses of organisms to drugs or nutrients (Nicholson et al, 2002; Lindon et al, 2004; Dumas et al, 2006b; Rezzi et al, 2007).”
BackgroundMethodInfluentialSelf-citationGut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
“synthesis of triglycerides in the liver [8, 9]; modulation of endocannabinoid system [10, 11]; modulation of choline metabolism (which is required for very-low-density lipoprotein synthesis and hepatic lipid export) [12, 13]; modulation of bile acid homeostasis [14, 15]; the ability to generate endogenous ethanol [16,…”
BackgroundTang, W. H. W., Wang, Z., Shrestha, K., Borowski, A. G., Wu, Y., Troughton, R. W., Klein, A. L., & Hazen, S. L. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.11.006 · Cited by 325
“Intestinal microbiota are implicated in the development of metabolic phenotypes such as obesity and insulin resistance[1].”
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Leser, T. D., & Mølbak, L. (2009) · Environmental Microbiology · doi:10.1111/j.1462-2920.2009.01941.x · Cited by 303
Programming infant gut microbiota: influence of dietary and environmental factors
Marques, T. M., Wall, R., Ross, R. P., Fitzgerald, G. F., Ryan, C. A., & Stanton, C. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.03.020 · Cited by 312
Role of the microbiota in inflammatory bowel diseases
Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease
Fouts, D. E., Torralba, M., Nelson, K. E., Brenner, D. A., & Schnabl, B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.019 · Cited by 311
“Conversion of choline into methylamines by microbiota in a susceptible mouse strain reduces the bioavailability of choline and mimics the effect of choline-deficient diets causing fatty liver disease [49].”
BackgroundEffects of the gut microbiota on obesity and glucose homeostasis
Greiner, T., & Bäckhed, F. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.01.002 · Cited by 304
Diamant, M., Blaak, E. E., & de Vos, W. M. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00797.x · Cited by 308
“Accumulating evidence indicates that the gut microbiota has a crucial role in conditions including obesity (10,11,18), diabetes (13,19,20), non-alcoholic fatty liver disease (21,22), inflammatory bowel disease (IBD) (23) and even cancer (24).”
BackgroundUnderstanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota
Xu, J., Chen, H., & Li, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21431 · Cited by 340
Gut microbiota: a new path to treat obesity
on behalf of the Obesity Programs of nutrition, E., Muscogiuri, G., Cantone, E., Cassarano, S., Tuccinardi, D., Barrea, L., Savastano, S., & Colao, A. (2019) · International Journal of Obesity Supplements · doi:10.1038/s41367-019-0011-7 · Cited by 354
Gut dysbiosis impairs recovery after spinal cord injury
Kigerl, K. A., Hall, J. C. E., Wang, L., Mo, X., Yu, Z., & Popovich, P. G. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151345 · Cited by 339
Metadata
- Authors
- Dumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., Mitchell, S. C., Holmes, E., McCarthy, M. I., Scott, J., Gauguier, D., & Nicholson, J. K.
- Affiliations
- Imperial College London (GB)
- *Department of Biological Chemistry and
- Centre for Human Genetics (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-08-15
- Volume
- 103
- Issue
- 33
- Pages
- 12511-12516
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1567909
- OpenAlex
- W2139464173
- Cited by
- 1,042
- References
- 0
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 29 · 2023: 26 · 2022: 43 · 2021: 57 · 2020: 52 · 2019: 80 · 2018: 70 · 2017: 67 · 2016: 86 · 2015: 72 · 2014: 63 · 2013: 80 · 2012: 62
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (057733, 066786)
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- gut microbiota, non-alcoholic fatty liver disease, insulin resistance, choline metabolism, phosphatidylcholine, trimethylamine N-oxide, methylamine, high-fat diet, impaired glucose homeostasis, metabotyping, host-microbe interactions, choline deficiency
- MeSH terms
- Animals, Body Weight, Dietary Fats, Fatty Liver, Glucose, Homeostasis, Insulin, Insulin Resistance, Lipids, Liver, Male, Methylamines, Mice, Inbred BALB C, Phenotype, Multivariate Analysis, Nuclear Magnetic Resonance, Biomolecular, Gastrointestinal Tract, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.